Skip to site content

Medication Safety Resources

Recent Safety Resources

Important FDA communications regarding the prescribing and monitoring of FDA approved medications and devices are listed here. Drug Safety Communications (DSC) are the result of pharmacovigilance through clinical research findings and post marketing surveillance data. A listing of recent DSC can be found on the FDA website Drug Safety Alerts (DSAs) provide important information about the safe and effective use of one or more medications. Drug safety alerts provide information about current topics and findings to help raise awareness and promote medication safety.

Stay Connected

Sign up on our NPTC LISTSERV for latest news, updates, discussions, and drug safety alerts and communications.

Additional Paxlovid Dose Packs Authorized for Patients with Moderate Renal Impairment

Drug-Safety Alert

April 15, 2022

The FDA) revised the EUA for Paxlovid, authorizing an additional dose pack with appropriate dosing for patients with moderate renal impairment.

Read More

FDA: Monitor Babies & Young Children Who Receive Injections of Iodine-Containing Contrast Media

Drug-Safety Communication

March 30, 2022

The FDA recommends that newborns and children through 3 years old have thyroid monitoring within 3 weeks post-injection of iodinated contrast media for medical imaging procedures.

Read More

Possible Increased Risk for Death with Umbralisib (Ukoniq)



Drug-Safety Communication

February 3, 2022

The FDA released a warning of possible increased risk of death with umbralisib (Ukoniq) used for the treatment of lymphoma.

Read More

Dental Problems Have Been Reported with Medicines Containing Buprenorphine that are Dissolved in the Mouth

Drug-Safety Communication

January 12, 2022

The dental problems, including tooth decay, cavities, oral infections, and loss of teeth, can be serious and have been reported even in patients with no history of dental issues.

Read More